Emergent BioSolutions, Gaithersburg, Maryland, USA.
Antimicrob Agents Chemother. 2013 Nov;57(11):5693-6. doi: 10.1128/AAC.00460-13. Epub 2013 Aug 26.
Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.
发展可在暴露后同时使用的炭疽对策需要了解这些产品之间的相互作用。抗炭疽免疫球蛋白静脉注射(AIGIV)是一种候选免疫疗法,含有针对保护性抗原(PA)的中和抗体,PA 是炭疽毒素的一种成分。我们在兔子中评估了 AIGIV 与 BioThrax(炭疽疫苗吸附剂)之间的相互作用。虽然疫苗接种并未改变 AIGIV 的药代动力学,但在接受 AIGIV 治疗的动物中,疫苗诱导的免疫反应被阻断。